We're sunsetting PodQuest on 2025-07-28. Thank you for your support!

#247 ‒ Preventing cardiovascular disease: the latest in diagnostic imaging, blood pressure, metabolic health, and more | Ethan Weiss, M.D.

2023/3/20

The Peter Attia Drive

AI Chapters

Chapters

Shownotes Transcript

No transcript made for this episode yet, you may request it for free.

#247 ‒ Preventing cardiovascular disease: the latest in diagnostic imaging, blood pressure, metabolic health, and more | Ethan Weiss, M.D.

The Peter Attia Drive

What is Ethan’s entrepreneurial work in the cardiometabolic disease space?

How do calcium scans and CT angiography inform ASCVD risk?

What can be learned from Peter’s historical CAC scores and CTA results?

How did Peter’s CTA results influence his decision to lower his apoB?

What are the differences between calcium scans and CT angiogram (CTA)?

How does Ethan make clinical decisions based on CTA results and plaque burden?

What improvements in CTA grading plaque lesions have shaped medical decisions?

Why does Ethan favor optimal medical therapy over stenting in most cases?

What is the potential of FFR CTA and medical therapy in eliminating ASCVD?

What is the significance of the fat attenuation index (FAI) in measuring plaque inflammation?

Do statins and exercise increase calcification risk, and what does this mean for ASCVD?

Why is there hesitation in using statins despite their proven benefits?

Should we accept higher blood pressure with age, and what is the importance of keeping it in check?

How does blood pressure variability impact health, and what is the best way to measure it?

What drugs are recommended for treating high blood pressure according to the ALLHAT trial?

What does the SPRINT trial suggest about the aggressive treatment of hypertension?

How does Ethan use various pharmacological agents to lower blood pressure in patients?

What do we know about the role of metabolic health in ASCVD?

How does fat storage capacity and location impact metabolic health and coronary artery disease?

Shownotes Transcript

#247 ‒ Preventing cardiovascular disease: the latest in diagnostic imaging, blood pressure, metabolic health, and more | Ethan Weiss, M.D. 02:12:54 Share

The Peter Attia Drive

What is Ethan’s entrepreneurial work in the cardiometabolic disease space?

How do calcium scans and CT angiography inform ASCVD risk?

What can be learned from Peter’s historical CAC scores and CTA results?

How did Peter’s CTA results influence his decision to lower his apoB?

What are the differences between calcium scans and CT angiogram (CTA)?

How does Ethan make clinical decisions based on CTA results and plaque burden?

What improvements in CTA grading plaque lesions have shaped medical decisions?

Why does Ethan favor optimal medical therapy over stenting in most cases?

What is the potential of FFR CTA and medical therapy in eliminating ASCVD?

What is the significance of the fat attenuation index (FAI) in measuring plaque inflammation?

Do statins and exercise increase calcification risk, and what does this mean for ASCVD?

Why is there hesitation in using statins despite their proven benefits?

Should we accept higher blood pressure with age, and what is the importance of keeping it in check?

How does blood pressure variability impact health, and what is the best way to measure it?

What drugs are recommended for treating high blood pressure according to the ALLHAT trial?

What does the SPRINT trial suggest about the aggressive treatment of hypertension?

How does Ethan use various pharmacological agents to lower blood pressure in patients?

What do we know about the role of metabolic health in ASCVD?

How does fat storage capacity and location impact metabolic health and coronary artery disease?

Shownotes Transcript

#247 ‒ Preventing cardiovascular disease: the latest in diagnostic imaging, blood pressure, metabolic health, and more | Ethan Weiss, M.D.